Biology subjects

Garnett, M.

Publications and source records attributed to Garnett, M..

11 recordsLinked to original sources

bioRxiv2026

STEER-seq: a recombinase based platform for pooled multimodal single-cell perturbation screening

Pooled gain-of-function screening is a powerful method for screening for transcription factors whose overexpression leads to changes in cellular identity. However, variable transgene copy number, integration site and genomic context from random viral integration can confound quantitative comparisons between perturbations. We present STEER-seq (Single-cell Transgene Expression via Exchange Recombination sequencing), a virus-free platform for pooled ORF gain-of-function screening in human induced pluripotent stem cells (hiPSCs). STEER-seq combines irreversible Bxb1-mediated integration at a defined genomic safe-harbour locus with promoterless donor libraries and barcode-enabled perturbation tracking, enabling single-copy expression from a common promoter and genomic context and direct recovery of perturbation identity by single-cell sequencing. In a focused haematopoietic screen, SPI1 expression alone was sufficient to drive differentiation towards HSC/MPP-like progenitors in the absence of exogenous cytokines, with transient induction generating progenitors that retained multilineage haematopoietic differentiation potential. Joint RNA-chromatin accessibility profiling linked transcription factor-induced transcriptional responses to chromatin remodelling and enabled reconstruction of perturbation-induced gene regulatory networks, including a RUNX2-driven osteoblast programme. Scaling STEER-seq to around 2,000 human coding sequences enabled systematic discovery of transcription factors capable of inducing distinct cell-state programmes, including neural progenitor-, melanocyte- and vascular smooth muscle-like states, as well as maintenance of pluripotency. STEER-seq provides a scalable, quantitative framework for single-cell and multimodal gain-of-function screening, enabling functional discovery and engineering of human cell identity.

genomics↗

bioRxiv2025

BEstimate: a computational tool for the design and interpretation of CRISPR base editing experiments

CRISPR base editors enable scalable targeted DNA mutagenesis and are a powerful tool for the interpretation of gene function, the study of variants of unknown significance, and disease modelling. Existing guide RNA (gRNA) design tools focus on engineering a small number of targeted variants in a given gene or lack comprehensive functional annotation of target sequences. Here we developed BEstimate, a flexible computational pipeline that systematically specifies base editor gRNA target sites, generates gRNA off-target predictions, and rich functional, structural and clinical annotations of targeted edits. BEstimate accommodates custom gRNA design against variant alleles, improving editing accuracy and facilitating the programmed reversion of disease variants. BEstimate is a freely available, versatile tool for designing gRNA libraries and analysing base editor screens.

bioinformatics↗

bioRxiv2024

Genetic interaction library screening with a next-generation dual guide CRISPR system

Pairwise perturbation of gene function using the CRISPR/Cas9 system has huge potential in screening for genetic interactions and synthetic lethal gene pairs to identify novel combination therapies for cancer. However, existing dual guide expression systems are cumbersome to clone, often result in a large proportion of undesired guide pairs and have imbalance of guide expression from the two positions. Here, we demonstrate a next-generation system for dual guide delivery based around a tRNA spacer that allows a single step cloning strategy, as little as 2% of undesired guide pairs, and highly balanced expression of the two guides. This system allows efficient library-scale screening for hundreds of thousands of genetic interactions using the well understood Streptococcus pyogenes Cas9 (SpCas9) system. We use this to screen a 100,136 guide pair library in colorectal cancer cells and successfully identify synthetic lethal genetic interactions between paralogs or other known interacting genes, establishing our method for performing efficient large scale genetic interaction screens. This system is versatile and can be used with most guide RNA vector systems, and for other uses of paired guide delivery such as improving single gene knockout efficiency or improving guide detection in single cell or optical CRISPR screens.

molecular biology↗

bioRxiv2022

Single-cell transcriptomic analysis of human pleura reveals stromal heterogeneity and informs in vitro models of mesothelioma

The pleural lining of the thorax regulates local immunity, inflammation and repair. A variety of conditions, both benign and malignant including pleural mesothelioma, can affect this tissue. A lack of knowledge concerning the mesothelial and stromal cells comprising the pleura has hampered the development of targeted therapies. Here we present the first comprehensive single cell transcriptomic atlas of the human parietal pleura and demonstrate its utility in elucidating pleural biology. We confirm the presence of known universal fibroblasts and describe novel, potentially pleural-specific, fibroblast subtypes. We also present transcriptomic characterisation of multiple in vitro models of benign and malignant mesothelial cells, and characterise these through comparison with in vivo transcriptomic data. While bulk pleural transcriptomes have been reported previously, this is the first study to provide resolution at single cell level. We expect our pleural cell atlas will prove invaluable to those studying pleural biology and disease. For example, it has already enabled us to shed light on the transdifferentiation of mesothelial cells allowing us to develop a simple method for prolonging mesothelial cell differentiation in vitro.

cancer biology↗

bioRxiv2021

A suspension technique for efficient large-scale cancer organoid culturing and perturbation screens

Organoid cell culture methodologies are enabling the generation of cell models from healthy and diseased tissue. Patient-derived cancer organoids that recapitulate the genetic and histopathological diversity of patient tumours are being systematically generated, providing an opportunity to investigate novel cancer biology and therapeutic approaches. The use of organoid cultures for many applications, including genetic and chemical perturbation screens, is limited due to the technical demands and cost associated with their handling and propagation. Here we report and benchmark a suspension culture technique for cancer organoids which allows for the expansion of models to tens of millions of cells with increased efficiency in comparison to standard organoid culturing protocols. Using whole-genome DNA and RNA sequencing analyses, as well as medium-throughput drug sensitivity testing and genome-wide CRISPR-Cas9 screening, we demonstrate that cancer organoids grown as a suspension culture are genetically and phenotypically similar to their counterparts grown in standard conditions. This culture technique simplifies organoid cell culture and extends the range of organoid applications, including for routine use in large-scale perturbation screens.

cancer biology↗

bioRxiv2020

Integrated cross-study datasets of genetic dependencies in cancer

CRISPR-Cas9 viability screens are increasingly performed at a genome-wide scale across large panels of cell lines to identify new therapeutic targets for precision cancer therapy. Integrating the datasets resulting from these studies is necessary to adequately represent the heterogeneity of human cancers and to assemble a comprehensive map of cancer genetic vulnerabilities. Here, we integrated the two largest public independent CRISPR-Cas9 screens performed to date (at the Broad and Sanger institutes) by assessing, comparing, and selecting methods for correcting biases due to heterogeneous single guide RNA efficiency, gene-independent responses to CRISPR-Cas9 targeting originated from copy number alterations, and experimental batch effects. Our integrated datasets recapitulate findings from the individual datasets, provide greater statistical power to cancer- and subtype-specific analyses, unveil additional biomarkers of gene dependency, and improve the detection of common essential genes. We provide the largest integrated resources of CRISPR-Cas9 screens to date and the basis for harmonizing existing and future functional genetics datasets.

bioinformatics↗

bioRxiv2020

A statistical framework for assessing pharmacological response and biomarkers with confidence

Drug high-throughput screenings across large molecular-characterised cancer cell line panels enable the discovery of biomarkers, and thereby, cancer precision medicine. The ability to experimentally generate drug response data has accelerated. However, this data is typically quantified by a summary statistic from a best-fit dose response curve, whilst neglecting the uncertainty of the curve fit and the potential variability in the raw readouts. Here, we model the experimental variance using Gaussian Processes, and subsequently, leverage this uncertainty for identifying associated biomarkers with a new statistical framework based on Bayesian testing. Applied to the Genomics of Drug Sensitivity in Cancer, in vitro screening data on 265 compounds across 1,074 cell lines, our uncertainty models identified 24 clinically established drug response biomarkers, and in addition provided evidence for 6 novel biomarkers. We validated our uncertainty estimates with an additional drug screen of 26 drugs, 10 cell lines with 8 to 9 replicates. Our method is applicable to drug high-throughput screens without replicates, and enables robust biomarker discovery for new cancer therapies.

cancer biology↗

bioRxiv2019

Stratification and prediction of drug synergy based on target functional similarity

Targeted mono-therapies in cancer are hampered by the ability of tumor cells to escape inhibition through rewiring or alternative pathways. Drug combination approaches can provide a means to overcome these resistance mechanisms. Effective use of combinations requires strategies to select combinations from the enormous space of combinations, and to stratify patients according to their likelihood to respond. We here introduce two complementary workflows: One prioritising experiments in high-throughput screens for drug synergy enrichment, and a consecutive workflow to predict hypothesis-driven synergy stratification. Both approaches only need data of efficacy of single drugs. They rely on the notion of target functional similarity between two target proteins. This notion reflects how similarly effective drugs are on different cancer cells as a function of cancer signaling pathways activities on those cells. Our synergy prediction workflow revealed that two drugs targeting either the same or functionally opposite pathways are more likely to be synergistic. This enables experimental prioritisation in high-throughput screens and supports the notion that synergy can be achieved by either redundant pathway inhibition or targeting independent compensatory mechanisms. We tested the synergy stratification workflow on seven target protein pairs (AKT/EGFR, AKT/MTOR, BCL2/MTOR, EGFR/MTOR, AKT/BCL2, AKT/ALK and AKT/PARP1, representing 29 combinations and predicted their synergies in 33 breast cancer cell lines (Pearsons correlation r=0.27). Additionally, we experimentally validated predicted synergy of the BRAF/Insulin Receptor combination (Dabrafenib/BMS-754807) in 48 colorectal cancer cell lines (r=0.5). In conclusion, our synergy prediction workflow can support compound prioritization in large scale drug screenings, and our synergy stratification workflow can select where the efficacy of drugs already known for inducing synergy is higher.

bioinformatics↗

bioRxiv2019

Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR/Cas9 screening

Many gene fusions have been reported in tumours and for most their role remains unknown. As fusions can be used clinically for diagnostic and prognostic purposes, and are targets for treatment, it is crucial to assess their functional implications in cancer. To investigate the role of fusions in tumor cell fitness, we developed a systematic analysis utilising RNA-sequencing data from 1,011 human cancer cell lines to functionally link 8,354 gene fusion events with genomic data, sensitivity to >350 anti-cancer drugs and CRISPR-Cas9 loss-of-fitness information. Established clinically-relevant fusions were readily identified. Overall, functional fusions were rare, including those involving cancer driver genes, suggesting that many fusions are dispensable for tumor cell fitness. Novel therapeutically actionable fusions involving RAF1, BRD4 and ROS1 were verified in new histologies. In addition, recurrent YAP1-MAML2 fusions were identified as activators of Hippo-pathway signaling in multiple cancer types, supporting therapeutic targeting of Hippo signalling. Our approach discriminates functional fusions, identifying new drivers of carcinogenesis and fusions that could have important clinical implications. SignificanceWe identify fusions as new potential candidates for drug repurposing and drivers of carcinogenesis. These results support histology agnostic marker-driven precision cancer medicine. Most fusions are not functional with implications for interpreting cancer fusions reported from clinical sequencing studies.

cancer biology↗

bioRxiv2018

JACKS: joint analysis of CRISPR/Cas9 knock-out screens

Genome-wide CRISPR/Cas9 knockout screens are revolutionizing mammalian functional genomics. Their range of applications remains limited by signal variability from different guide RNAs targeting the same gene, which confounds analysis, and dictates large experiment sizes. To address this problem, we report JACKS, a Bayesian method that jointly analyses screens performed with the same guide RNA library. Modeling the variable guide efficacies greatly improves hit identification, and allows a 2.5-fold reduction in required cell numbers without sacrificing performance compared to current analysis standards.

genomics↗

bioRxiv2018

Integrative analysis of pharmacogenomics in major cancer cell line databases using CellMinerCDB

As precision medicine demands molecular determinants of drug response, CellMinerCDB provides (https://discover.nci.nih.gov/cellminercdb/) a web-based portal for multiple forms of pharmacological, molecular, and genomic analyses, unifying the richest cancer cell line datasets (NCI-60, NCI-SCLC, Sanger/MGH GDSC, and Broad CCLE/CTRP). CellMinerCDB enables genomic and pharmacological data queries for identifying pharmacogenomic determinants, drug signatures, and gene regulatory networks for researchers without requiring specialized bioinformatics support. It leverages overlaps of cell lines and tested drugs to allow assessment of data reproducibility. It builds on the complementarity and strength of each dataset. A panel of 41 drugs evaluated in parallel in the NCI-60 and GDSC is reported, supporting drug reproducibility across databases, repositioning of bisacodyl and acetalax for triple negative breast cancer, and identifying novel drug response determinants and genomic signatures for topoisomerase inhibitors and schweinfurthins in development. CellMinerCDB also allowed the identification of LIX1L as a novel mesenchymal gene regulating cellular migration and invasiveness.

bioinformatics↗